Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas

NCT03930771 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped the study had a low accrual rate

Conditions

Recurrent Pituitary Adenomas

Interventions

DRUG: Capecitabine
DRUG: Temozolomide

Sponsor

Weill Medical College of Cornell University